Literature DB >> 32534357

Effect of epiberberine from Coptis chinensis Franch on inhibition of tumor growth in MKN-45 xenograft mice.

Min Yu1, Li Ren1, Fan Liang1, Yaru Zhang1, Lingmin Jiang2, Wenyu Ma1, Chunming Li2, Xuegang Li3, Xiaoli Ye4.   

Abstract

BACKGROUND AND
PURPOSE: Gastric cancer is one of the major malignancies worldwide. Epiberberine (EPI) is a major alkaloid from Coptis chinensis Franch and the antitumor property of EPI remains poorly understood.
METHOD: The inhibition on gastric cancer cells was observed by MTT assays and colony formation experiments. The apoptosis, cell cycle, and reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) in gastric cancer cells were analyzed by Flow cytometry. The anti-tumor effect of EPI was evaluated with the MKN-45-beraring nude mice, and the potential mechanisms were explored by RNA-seq, qPCR, siRNA silencing and western blotting.
RESULTS: EPI inhibited the proliferation of human gastric cancer cell lines MKN-45 (harboring wild-type p53) and HGC-27 (harboring mutant p53) in a dose dependent manner. EPI induced the apoptosis and cell cycle arrest in these two cell lines, of which MKN-45 cells are more sensitive to EPI than HGC-27 cells. Further experiments indicated that EPI induced the accumulation of ROS and decreased of ΔΨm in MKN-45 cells. The significant differentially expressed genes obtained by RNA-seq were distinctly enriched in the p53 signaling pathway. The apoptosis induced by EPI in MKN-45 cells would be effectively inhibited with the treatment of p53 siRNA and p53 inhibitor PFT-α. Western blotting demonstrated that EPI diminished the expression of Bcl-2 and XIAP, and increased those of p53, Bax, p21, p27, Cytochrome C and Cleaved-caspase 3. Animal experiments confirmed that EPI significantly alleviated tumor growth in MKN-45 xenograft mice via p53/Bax pathway.
CONCLUSIONS: These data indicated that EPI could be a novel anti-tumor candidate against MKN-45-related gastric cancer via targeting p53-dependent mitochondria-associated pathway.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; Epiberberine; Gastric cancer; p53

Year:  2020        PMID: 32534357     DOI: 10.1016/j.phymed.2020.153216

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  10 in total

1.  Characterizing the Antitumor Effect of Coptis chinensis and Mume Fructus against Colorectal Cancer Based on Pharmacological Analysis.

Authors:  RuiJiao Gao; Ying Lv
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

Review 2.  The Potential Anticancer Activity of Phytoconstituents against Gastric Cancer-A Review on In Vitro, In Vivo, and Clinical Studies.

Authors:  Sylwia Nakonieczna; Aneta Grabarska; Wirginia Kukula-Koch
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

3.  Nuclear factor-κB inhibitor Bay11-7082 inhibits gastric cancer cell proliferation by inhibiting Gli1 expression.

Authors:  Yan Yan; Heya Qian; Ying Cao; Tao Zhu
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

Review 4.  Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids.

Authors:  Mounir Tilaoui; Hassan Ait Mouse; Abdelmajid Zyad
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

Review 5.  Based on Network Pharmacology to Explore the Potential Bioactive Compounds and Mechanisms of Zuojin Pill for the Treatment of Ulcerative Colitis.

Authors:  Ying Wei; Sichen Ren; Ruilin Wang; Manyi Jing; Honghong Liu; Min Wang; Hongtao Song; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-26       Impact factor: 2.629

6.  Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway.

Authors:  Mei Li; Cailong Chen; Qian Wang; Xiaolu Jiang; Lanlan Tan; Ying Huang; Yan Zhang; Zubin Zhang
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

7.  Anticancer Action of Xiaoxianxiong Tang in Non-Small Cell Lung Cancer by Pharmacological Analysis and Experimental Validation.

Authors:  Rongzhen Ding; Lijing Jiao; Shuliu Sang; Yinan Yin; Yichao Wang; Yabin Gong; Ling Xu; Ling Bi
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-13       Impact factor: 2.629

8.  The tRNA-Derived Fragment tRF-24-V29K9UV3IU Functions as a miRNA-like RNA to Prevent Gastric Cancer Progression by Inhibiting GPR78 Expression.

Authors:  Hui Wang; Weikang Huang; Xirui Fan; Xiaoxue He; Sijin Chen; Su Yu; Yan Zhang
Journal:  J Oncol       Date:  2022-04-29       Impact factor: 4.375

9.  Network pharmacology and molecular docking to elucidate the mechanism of pulsatilla decoction in the treatment of colon cancer.

Authors:  Huan Liu; Yuting Hu; Baoyu Qi; Chengqiu Yan; Lin Wang; Yiwen Zhang; Liang Chen
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

Review 10.  Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Authors:  Luying He; Zhangfeng Zhong; Man Chen; Qilian Liang; Yitao Wang; Wen Tan
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.